Anti-CD19 chimeric antigen receptor T cell therapy - Sinobioway Cell Therapy

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Sinobioway Cell Therapy

Alternative Names: CAR-CD19-modified T cells; CD19-targeted CAR-T cells

Latest Information Update: 06 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sinobioway Cell Therapy
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma

Most Recent Events

  • 10 Apr 2017 Sinobioway Cell Therapy and Jiangsu Cancer Institute & Hospital plan a phase I trial for B-cell lymphoma (Second-line therapy or greater, CD19 positive) in China (NCT03086954)
  • 02 Jul 2015 Phase-II clinical trials in Diffuse large B cell lymphoma (Recurrent, Refractory metastatic disease) in China (Parenteral) (NCT02728882)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top